Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical

[En bild som visar text, skärmbild, Teckensnitt, logotyp

AI-genererat innehåll kan vara felaktigt.]Norwegian pharma company Navamedic and German pharma company Evolsin Medical, have signed an exclusive distribution agreement for Germany. The first product to be launched in Germany will be Navamedic's extra effective antiperspirant product Dermix® Absolut Torr® with a private label tailored for the German market: Evolsin® 7-Tage Antitranspirant

"We are excited about the collaboration with Evolsin and believe that Absolut Torr will have a good potential in Germany. In addition, the collaboration opens for additional products for the German market."says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.

"Evolsin® 7-Tage Antitranspirant fits well into our established skin care business where we also have a strong digital presence." Daniel Dilges, Chief Executive Officer of Evolsin, adds.

[image]

Dermix Absolut Torr is classified as a cosmetic product, developed and manufactured in Sweden. It comes in three different presentations, roll-on, dab -on and wipes. Absolut Torr has so far been launched in the Nordics, the Middle East and Balkans. It is also sold under the brand Dermix Absolut Dry®. With its 84 million inhabitants, Germany will be the single largest market to launch so far. The launch in the Germany is expected early 2026.

For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic    Lars Hjarrand, CFO, Navamedic Mobile: +47 951 78 680                                          Mobile: +47 917 62 842 E-mail: kathrine@navamedic.com                           E-mail: lars.hjarrand@navamedic.com

Daniel Dilges, CEO, Evolsin Mobile: +49 6081 947 0926 E-mail: daniel.dilges@evolsin-medical.com

About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, addiction, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

About Evolsin Evolsin® Medical is a German, family-owned medical skin care business. Our goal is to provide effective relief for people with chronic skin problems through clinically tested, effective products. All our products are developed and produced in the European Union. We consistently avoid parabens, antibiotics, Coritson and perfume.

In addition to the health of our patients, we as parents and grandparents are very concerned about climate protection as well as the social cohesion of our community. For this reason, we support social and ecological projects in our region and are continuously working to reduce the CO2 footprint of Evolsin and its products.

For more information, please visit Evolsin-medical.com